Results 11 to 20 of about 209,258 (305)
The Oncologist, 2010 AbstractInhibitors of mammalian target of rapamycin (mTOR) have been approved for the treatment of renal cell carcinoma and appear to have a role in the treatment of other malignancies. The primary objective of this drug review is to provide pharmacokinetic and dynamic properties of the commonly used drugs everolimus and temsirolimus.
Heinz-Josef, Klümpen +3 more
openaire +3 more sources
Targeting ganglioneuromas with mTOR inhibitors [PDF]
Molecular & Cellular Oncology, 2021 We recently identified activated protein kinase B (PKB/AKT) as a tumorigenic driver in childhood ganglioneuroma. Inhibition of the mechanistic target of rapamycin (mTOR), a serine/threonine kinase downstream of AKT, effectively reduced the tumor burden in zebrafish with ganglioneuroma. We propose a clinical trial of mTOR inhibitors as a means to shrink
Ting Tao +3 more
openaire +3 more sources
Predicting mTOR inhibitors with a classifier using recursive partitioning and Naïve Bayesian approaches. [PDF]
PLoS ONE, 2014 BACKGROUND: Mammalian target of rapamycin (mTOR) is a central controller of cell growth, proliferation, metabolism, and angiogenesis. Thus, there is a great deal of interest in developing clinical drugs based on mTOR.
Ling Wang +5 more
doaj +1 more source
Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention
Pharmaceutics, 2021 The phosphatidylinositol 3-kinase (PI3K)/serine-threonine kinase (Akt)/mammalian target of the rapamycin (mTOR)-signaling pathway has been suggested to have connections with the malignant transformation, growth, proliferation, and metastasis of various ...
Nazanin Momeni Roudsari +11 more
doaj +1 more source
Updates of mTOR Inhibitors [PDF]
Anti-Cancer Agents in Medicinal Chemistry, 2010 Mammalian target of rapamycin (mTOR) is a central controller of cell growth, proliferation, metabolism and angiogenesis. mTOR signaling is often dysregulated in various human diseases and thus attracts great interest in developing drugs that target mTOR.
Hongyu, Zhou, Yan, Luo, Shile, Huang
openaire +2 more sources
mTOR inhibitors: An overview [PDF]
Liver Transplantation, 2001 Inhibitors of the mammalian target of rapamycin are a new class of immunosuppressants. In contrast to other macrolides, such as tacrolimus and cyclosporine A, they do not inhibit calcineurin and thus signal I of T-cell activation.
P, Neuhaus, J, Klupp, J M, Langrehr
openaire +2 more sources
mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms. [PDF]
PLoS ONE, 2013 BACKGROUND:Dysregulated signaling of the JAK/STAT pathway is a common feature of chronic myeloproliferative neoplasms (MPN), usually associated with JAK2V617F mutation.
Costanza Bogani +7 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Background: Mammalian target of rapamycin (mTOR) inhibitors, such as everolimus and sirolimus, may be efficacious in preserving renal function in liver transplantation (LT) recipients while preventing hepatocellular carcinoma (HCC) recurrence.Materials ...
Pil Soo Sung +17 more
doaj +1 more source
Contemporary Oncology, 2020 The phosphoinositide 3-kinase (PI3K) pathway is an important regulator of cell proliferation and metabolism. PI3K activation initiates a signal transduction cascade, of which the major effectors are the kinases AKT and mTOR.
Ilham Kandoussi +4 more
doaj +1 more source
Frontiers in Oncology, 2020 Glioblastoma (GB) is the most malignant and aggressive form of brain tumor, characterized by frequent hyperactivation of the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) signaling pathway.
Qin Xia +5 more
doaj +1 more source